$151 Million is the total value of Lynx1 Capital Management LP's 18 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STOK | New | STOKE THERAPEUTICS INC | $6,738,007 | – | 1,710,154 | +100.0% | 4.46% | – |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $3,175,848 | – | 1,363,025 | +100.0% | 2.10% | – |
| SLN | New | SILENCE THERAPEUTICS PLCads | $2,315,428 | – | 235,787 | +100.0% | 1.53% | – |
| New | BIONOMICS LIMITEDads | $2,201,882 | – | 815,512 | +100.0% | 1.46% | – | |
| CCCC | New | C4 THERAPEUTICS INC | $1,895,768 | – | 1,019,230 | +100.0% | 1.25% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $1,052,315 | – | 1,766,815 | +100.0% | 0.70% | – |
| New | ZURA BIO LTD | $65,452 | – | 9,917 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MERUS N V | 8 | Q3 2023 | 21.9% |
| ALPINE IMMUNE SCIENCES INC | 8 | Q3 2023 | 20.2% |
| CYMABAY THERAPEUTICS INC | 8 | Q3 2023 | 10.0% |
| THESEUS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.6% |
| PIERIS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| KINNATE BIOPHARMA INC | 7 | Q3 2023 | 18.0% |
| PARDES BIOSCIENCES INC | 7 | Q2 2023 | 11.0% |
| PASSAGE BIO INC | 7 | Q3 2023 | 4.0% |
| BELLUS HEALTH INC NEW | 6 | Q1 2023 | 22.7% |
| CABALETTA BIO INC | 4 | Q3 2023 | 22.6% |
View Lynx1 Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-04-23 |
| SC 13G | 2024-04-01 |
| SC 13G | 2024-03-29 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Lynx1 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.